Literature DB >> 27404493

CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.

Burcin Kepez Yildiz1, Sengul Ozdek, Mehmet Ali Ergun, Sezen Ergun, Fulya Yaylacioglu Tuncay, Sehri Elbeg.   

Abstract

PURPOSE: The aim of this study was to evaluate the prevalence of single nucleotide polymorphisms (SNPs) in complement factor H (CFH) Y402H and VEGF rs2146323 and rs699947 in exudative age-related macular degeneration (AMD) and their relationship with intravitreal anti-VEGF treatment response.
METHODS: A total of 109 exudative AMD patients and 70 controls were included. Patients were classified as 'good responders' and 'nonresponders' based on the changes in best corrected visual acuity, central foveal thickness, lesion size, and the persistence of retinal hemorrhage after three dosages of anti-VEGF. We examined CFH, VEGF rs2146323 and rs699947 SNPs, and plasma interleukin-6 (IL-6) levels in both groups.
RESULTS: In total, 42 patients (38.5%) and 11 controls (15.7%) had homozygote wild genotype TT (p = 0.002). The variant C allele frequency was 45% in controls and 31.7% in patients (p = 0.011). A and C allele frequencies for VEGF rs699947 and rs2416323 were similar between the control and patient groups (p = 0.947, p = 0.378). Both SNPs were similar in responders and nonresponders. No significant difference was detected between plasma IL-6 levels of the control and AMD groups (p = 0.594), but the levels were higher in good responders than nonresponders (p < 0.001).
CONCLUSION: CFH Y402H SNP might be protective for AMD in the Turkish population. VEGF rs2146323 and rs699947 SNPs have no relationship to exudative AMD formation, and none of these seem to have any effect on anti-VEGF response.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27404493     DOI: 10.1159/000446186

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  6 in total

1.  Interaction of two functional genetic variants LOXL1 rs1048661 and VEGFA rs3025039 on the risk of age-related macular degeneration in Chinese women.

Authors:  Han Chen; Miao Mo; Guang-Yu Liu; Yang-Ming Gong; Ke-Da Yu; Ge-Zhi Xu
Journal:  Ann Transl Med       Date:  2020-07

2.  Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.

Authors:  Agnieszka Kubicka-Trząska; Katarzyna Żuber-Łaskawiec; Sylwia Dziedzina; Marek Sanak; Bożena Romanowska-Dixon; Izabella Karska-Basta
Journal:  Medicina (Kaunas)       Date:  2022-05-13       Impact factor: 2.948

Review 3.  Biomarkers as Predictive Factors of Anti-VEGF Response.

Authors:  Miriam Bobadilla; Ana Pariente; Ana I Oca; Rafael Peláez; Álvaro Pérez-Sala; Ignacio M Larráyoz
Journal:  Biomedicines       Date:  2022-04-26

Review 4.  Genetics of age-related macular degeneration (AMD).

Authors:  Margaret M DeAngelis; Leah A Owen; Margaux A Morrison; Denise J Morgan; Mingyao Li; Akbar Shakoor; Albert Vitale; Sudha Iyengar; Dwight Stambolian; Ivana K Kim; Lindsay A Farrer
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

Review 5.  Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

Authors:  Laura Lorés-Motta; Eiko K de Jong; Anneke I den Hollander
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

6.  VEGFA Haplotype and VEGF-A and VEGF-R2 Protein Associations with Exudative Age-Related Macular Degeneration.

Authors:  Alvita Vilkeviciute; Dzastina Cebatoriene; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  Cells       Date:  2022-03-15       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.